1 2 3 4

SOTIO Presents Poster on CLAUDIO-01 Trial at ESMO Congress

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting a trial-in-progress poster at the European Society for Medical Oncology Congress taking place October 20-24, 2023 in Madrid, Spain. 


SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

  • SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need.
  • Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors.
  • Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million.

SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer

  • Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population.
  • Phase 1/2 study is evaluating SOT102, a Claudin 18.2 antibody-drug conjugate, for treatment of gastric and pancreatic cancers.